Cargando…
Current Progress of RNA Aptamer-Based Therapeutics
Aptamers are single-stranded nucleic acids that specifically recognize and bind tightly to their cognate targets due to their stable three-dimensional structure. Nucleic acid aptamers have been developed for various applications, including diagnostics, molecular imaging, biomarker discovery, target...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486975/ https://www.ncbi.nlm.nih.gov/pubmed/23130020 http://dx.doi.org/10.3389/fgene.2012.00234 |
_version_ | 1782248425182461952 |
---|---|
author | Zhou, Jiehua Bobbin, Maggie L. Burnett, John C. Rossi, John J. |
author_facet | Zhou, Jiehua Bobbin, Maggie L. Burnett, John C. Rossi, John J. |
author_sort | Zhou, Jiehua |
collection | PubMed |
description | Aptamers are single-stranded nucleic acids that specifically recognize and bind tightly to their cognate targets due to their stable three-dimensional structure. Nucleic acid aptamers have been developed for various applications, including diagnostics, molecular imaging, biomarker discovery, target validation, therapeutics, and drug delivery. Due to their high specificity and binding affinity, aptamers directly block or interrupt the functions of target proteins making them promising therapeutic agents for the treatment of human maladies. Additionally, aptamers that bind to cell surface proteins are well suited for the targeted delivery of other therapeutics, such as conjugated small interfering RNAs (siRNA) that induce RNA interference (RNAi). Thus, aptamer-siRNA chimeras may offer dual-functions, in which the aptamer inhibits a receptor function, while the siRNA internalizes into the cell to target a specific mRNA. This review focuses on the current progress and therapeutic potential of RNA aptamers, including the use of cell-internalizing aptamers as cell-type specific delivery vehicles for targeted RNAi. In particular, we discuss emerging aptamer-based therapeutics that provide unique clinical opportunities for the treatment various cancers and neurological diseases. |
format | Online Article Text |
id | pubmed-3486975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-34869752012-11-05 Current Progress of RNA Aptamer-Based Therapeutics Zhou, Jiehua Bobbin, Maggie L. Burnett, John C. Rossi, John J. Front Genet Genetics Aptamers are single-stranded nucleic acids that specifically recognize and bind tightly to their cognate targets due to their stable three-dimensional structure. Nucleic acid aptamers have been developed for various applications, including diagnostics, molecular imaging, biomarker discovery, target validation, therapeutics, and drug delivery. Due to their high specificity and binding affinity, aptamers directly block or interrupt the functions of target proteins making them promising therapeutic agents for the treatment of human maladies. Additionally, aptamers that bind to cell surface proteins are well suited for the targeted delivery of other therapeutics, such as conjugated small interfering RNAs (siRNA) that induce RNA interference (RNAi). Thus, aptamer-siRNA chimeras may offer dual-functions, in which the aptamer inhibits a receptor function, while the siRNA internalizes into the cell to target a specific mRNA. This review focuses on the current progress and therapeutic potential of RNA aptamers, including the use of cell-internalizing aptamers as cell-type specific delivery vehicles for targeted RNAi. In particular, we discuss emerging aptamer-based therapeutics that provide unique clinical opportunities for the treatment various cancers and neurological diseases. Frontiers Media S.A. 2012-11-02 /pmc/articles/PMC3486975/ /pubmed/23130020 http://dx.doi.org/10.3389/fgene.2012.00234 Text en Copyright © 2012 Zhou, Bobbin, Burnett and Rossi. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. |
spellingShingle | Genetics Zhou, Jiehua Bobbin, Maggie L. Burnett, John C. Rossi, John J. Current Progress of RNA Aptamer-Based Therapeutics |
title | Current Progress of RNA Aptamer-Based Therapeutics |
title_full | Current Progress of RNA Aptamer-Based Therapeutics |
title_fullStr | Current Progress of RNA Aptamer-Based Therapeutics |
title_full_unstemmed | Current Progress of RNA Aptamer-Based Therapeutics |
title_short | Current Progress of RNA Aptamer-Based Therapeutics |
title_sort | current progress of rna aptamer-based therapeutics |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486975/ https://www.ncbi.nlm.nih.gov/pubmed/23130020 http://dx.doi.org/10.3389/fgene.2012.00234 |
work_keys_str_mv | AT zhoujiehua currentprogressofrnaaptamerbasedtherapeutics AT bobbinmaggiel currentprogressofrnaaptamerbasedtherapeutics AT burnettjohnc currentprogressofrnaaptamerbasedtherapeutics AT rossijohnj currentprogressofrnaaptamerbasedtherapeutics |